PR Newswire All News ReleasesQwen · 实盘不做把握 2/10不做原因:消息已过时
北京时间·🕒 发布 09:03:00·⟳ 抓取 09:03:13 +13s·⚡ 决策 09-01 09:04:24 +1m11s·56.7 天前
Rosen律所发布Capricor Therapeutics（CAPR）证券欺诈集体诉讼首席原告征集公告
本条信号是Rosen律所通过PR Newswire发布的首席原告征集广告（Attorney Advertising），不是新的企业/市场事件。底层负面催化——FDA未同意Capricor对Deramiocel BLA统计分析计划的变更——发生在2025年12月至2026年7月期间，距今已超过一个月，股价早已反映。本条公告未披露任何新增事实（无新监管决定、无新数据、无金额、无指引变化），不构成可交易催化。此外，CAPR.US行情工具返回no_price，无法确认流动性和可执行性。
📄 原文PR Newswire All News Releases↗ 原文
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of s…
不做 Capricor Therapeutics（CAPR.US）
本条为Rosen律所首席原告征集广告（Attorney Advertising），底层利空（Deramiocel BLA统计分析计划变更未获FDA同意）早在集体诉讼期间（截至2026-07-26）已公开并被市场定价，距今超过一个月，无新增事实。且行情工具无法取得CAPR实时报价，流动性和可执行性无法确认。不构成可交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Rosen律所发布Capricor Therapeutics证券集体诉讼首席原告征集公告，属律所营销性质PR。底层利空（Deramiocel BLA统计分析计划变更未获FDA同意）的集体诉讼期间截至2026-07-26，距当前已超过一个月，相关信息早已公开并被市场定价。本条公告无新增事实、无新监管动作、无量化增量，不构成交易催化。行情工具亦无法取得CAPR实时报价。结论：不做。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:先例研究不适用于本条信号：底层事件已过时一个多月，无新催化可定价
方向:不适用——本条为陈旧利空的律所营销重述，非新催化
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 1 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 118 ms
{"result": "search_processed_events:agent query=`capr class action deramiocel | capricor fda statistical analysis plan | capricor therapeutics securities fraud lawsuit`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、1463 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 降级 stock_tools HTTP · 1,059 ms
取价失败: Futu returned no quote
原文全文
展开原文 · 4,273 字
NEW YORK, Aug. 31, 2026 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.
So what: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants made materially false and/or misleading statements and or failed to disclose that: (1) Capricor adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel, a cell therapy; (2) the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel Biologics License Application (the "BLA"); (3) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) as a result of the foregoing, defendants' positive statements about Capricor's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.
So what: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants made materially false and/or misleading statements and or failed to disclose that: (1) Capricor adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel, a cell therapy; (2) the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel Biologics License Application (the "BLA"); (3) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) as a result of the foregoing, defendants' positive statements about Capricor's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Capricor class action, go to https://rosenlegal.com/cases/capricor-therapeutics-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。